Gonorrhea Therapeutics Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2019 to 2029

Published on : Jul-2019 | List of Tables : 52 | List of Figures : 202 | No. of Pages : 170 | Report Code : FACT3761MR | Format :

Gonorrhea Therapeutics Market in Numbers:

  • The gonorrhea therapeutics market recorded ~3% CAGR during the period, 2014 to 2018. Gonorrhea emerged as a public threat worldwide with increasing prevalence of the antibiotic-resistant strains, which sustained the demand for gonorrhea therapeutics in recent years.
  • Revenues from gonorrhea therapeutics around the world is estimated at ~US$ 970 Mn in 2019, and record a 4% Y-o-Y over 2018. The gonorrhea therapeutics industry will remain sustained by inclination of the scientific community toward development of alternative therapies and new antibiotics.
  • North America remains the most attractive market for gonorrhea therapeutics, primarily upheld by growing government initiatives to compact antibiotic resistance. The US government has released a plan to ‘Combat Antibiotic-Resistant Bacteria’ (CARB) that holds opportunistic potential for companies with strong regional presence.
  • Research on the drug-resistance gonorrhea, which is likely to pave a potential pipeline for future treatment, is likely to favor the gonorrhea therapeutics industry.
gonorrhea therapeutic market snapshot

For more insights on the gonorrhea therapeutics market, request for the report sample

Competition Landscape

According to our study, the gonorrhea therapeutics market will remain a fairly fragmented landscape, with a large number of contenders collectively holding relatively greater shares than the frontrunners and competitors in the market. With ~40% market shares, the contenders are competing with product innovations in active therapy areas, targeted drug delivery, and capacity expansion to meet growing demand for therapeutics abreast escalating prevalence of gonorrhea. Frontrunners in the gonorrhea therapeutics market are focusing more on diagnostic tests and services, and R&D dedicated to biosimilars and generics.

The stakeholders in the gonorrhea therapeutics market are more focused on strengthening their distribution in untapped markets, even as entering into strategic partnerships with local distributors to enhance their supplier force and propel sales. Growing prevalence of antibiotic-resistant gonorrhea has meant that the need for new drugs is evident, as a significant chunk of the global demographic falls prey to the Neisseria gonorrhea bacteria annually. Although progress in gonorrhea vaccines has slugged in the past, recent advances allude an uptick, with conserved vaccine antigens that stimulate bactericidal antibodies being recognized.

New drug developments and laser-sharp focus on quick approvals will remain key winning imperatives for stakeholders in the gonorrhea therapeutics market, in turn complementing their brand repositioning strategies. Prospects for the gonorrhea therapeutics market seem bullish, with key players increasingly vying for geographical presence, new drug launches, and stable supply chain logistics.

gonorrhea therapeutic market attractiveness index analysis

For more insights into the competitive landscape of the gonorrhea therapeutics market, request for the report sample

Key Factors Driving Growth in Gonorrhea Therapeutics Market

  • Increasing prevalence of gonorrhea, coupled with the rising public awareness about STDs (Sexually-Transmitted Diseases), and advances in relevant diagnostic methods, are the key growth determinants of the gonorrhea therapeutics market.
  • Rising incidence of gonorrhea has led to the advent of new diagnostic tests, such as nucleic acid amplification tests (NAATs), which enable early screening to keep the infection from spreading to the upper genital tract.
  • Preference for NAATs over traditional cultures has grown significantly in recent years owing to their improved sensitivity and selectivity for Neisseria gonorrhoeae at rectal and oropharyngeal sites in men. Such increased availability and adoption of testing modalities is driving the demand for gonorrhea therapeutics.
  • Low cost of gonorrhea therapeutics continues to favor its market prospects, while stakeholders eye to capitalize on the pricing value of widely used STD drugs, such as Ceftriaxone.
  • Rapid improvements in healthcare infrastructure, particularly in developed regions are highly likely to create fresh growth avenues in the form of advanced and more effective drugs, thereby escalating the attractiveness of the gonorrhea therapeutics market.
gonorrhea therapeutic market pa image

For more information on growth influencers of the gonorrhea therapeutics market, request for the report sample

Key Challenges Faced by Stakeholders in Gonorrhea Therapeutics Market

  • The advent of new antibiotic-resistant strains continues to impede the prospects of the gonorrhea therapeutics market by making the currently available drugs lose their effectiveness in fighting the bacterium. The insidious nature of gonorrhea, owing to its growing success at evolving to evade the antibiotics prescribed to treat remains a significant pain-point for stakeholders.
  • The social stigma surrounding open discussions about STD, particularly in underdeveloped and developing countries has been hampering the true potential of the gonorrhea therapeutics market. Due to poor social acceptance of infection in line with the lack of openness and diverse communication regarding sexuality, the adoption of gonorrhea therapeutics is witnessing a restrictive growth.

Gonorrhea Therapeutics Market – Additional Insight

Paramount Emphasis on Antibiotic R&D to Favor Gains

Antimicrobial resistance (AMR) has become a rapidly growing global public health threat. With AMR making more than 375 million annual new cases of sexually-transmitted infections (STIs) that are stringent to treat, there has emerged a dire need to tackle this upcoming health crisis. The bacteria that causes gonorrhea is particularly prone to drug resistance, and is classed as ‘high priority’ for renewed antibiotic R&D by leading health organizations.

Turning into a global public health concern, in line with the high unmet need for gonorrhea treatment, growing prevalence of this infection has propelled organizations to collaborate and develop a novel treatment in this light. For instance, Entasis Therapeutics and the Global Antibiotic Research & Development Partnership (GARDP) had collaborated to co-develop a new drug zoliflodacin, specifically to treat drug-resistant gonorrhea, while hoping to provide a solution. Zoliflodacin is a new and first-in-class oral antibiotic that inhibits DNA synthesis in a different way than currently approved antibiotics. Zoliflodacin has been awarded fast track status by the FDA for development as oral treatment for gonorrhea infections, which is likely to translate into significant gains for the gonorrhea therapeutics market in the years to come.

Research Scope

gonorrhea therapeutic market taxonomy

Gonorrhea Therapeutics Market – Research Methodology

An authentic methodology and holistic approach lay the base of the actionable information mentioned in the report on gonorrhea therapeutics market. The Fact.MR study provides detailed information about the growth forecast of gonorrhea therapeutics market, along with an organized breakdown of the factors shaping the dynamics of the market.

Thorough primary and secondary has been employed to accumulate and present valuable insights into the projection analysis of gonorrhea therapeutics market. The report on gonorrhea therapeutics market has also passed through several validation tunnels to ensure that that insights covered in the report are exclusive and one of its kind.

Research Methodology of this Report.

A recently compiled report of Fact.MR, titled “Gonorrhea Therapeutics Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2019-2029,” gives a detailed evaluation on the gonorrhea therapeutics market worldwide. Size of the gonorrhea therapeutics market has been analyzed thoroughly and is provided in terms of value and volume.

Chapter 1- Gonorrhea Therapeutics Market Executive Summary

A concise summary of the gonorrhea therapeutics market has been provided in the first chapter of the report, which sheds light on the key trends in the market and information related to the market structure. Opportunity assessment for various companies operating in the gonorrhea therapeutics market is given with the aid of Wheel of Fortune. Latest trends that are shaping the growth of the gonorrhea therapeutics market are also given in the report.

Chapter 2- Gonorrhea Therapeutics Market Overview

The report offers a landscape view of the gonorrhea therapeutics market, which includes the introduction and definition of the key product. A systematic breakdown of the gonorrhea therapeutics market is also mentioned in this chapter of the report.

Chapter 3- Gonorrhea Therapeutics Key Market Trends

In this chapter of the report, information related to the key trends that are impacting the growth of the market are mentioned. The unique development trends in the gonorrhea therapeutics market are also detailed in this part of the report.

Chapter 4- Gonorrhea Therapeutics Key Success Factors

This chapter of the report provides information regarding the key factors that are influencing the growth and success of the market. It also sheds light on the investment feasibility matrix and product life cycle assessment.

Chapter 5- Gonorrhea Therapeutics Market Background

This section of the report on gonorrhea therapeutics market sheds light on the background of the market, wherein myriad factors that have been shaping the adoption of gonorrhea therapeutics are given.

Chapter 6- Global Gonorrhea Therapeutics Market Demand (in value US$ Mn) Analysis 2014 - 2018 and Forecast, 2019-2029

The detailed information and forecast on gonorrhea therapeutics market has been provided in this part of the report. Imperative numbers, such as historical, current and forecast size of the gonorrhea therapeutics market is given in terms of value.

Chapter 7 – Gonorrhea Therapeutics Market Background

This chapter of the report on gonorrhea therapeutics market provides a detailed outlook of the market background, wherein a plethora of factors impacting the sales of gonorrhea therapeutics are mentioned in detail. This section of the report also provides information related to the applications of the key product to assist the market enthusiasts gauge the growth of gonorrhea therapeutics market in a better way.

Chapter 8 - Global Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029, by Region

This section of the report on gonorrhea therapeutics market provides information related to market particulars, breakdown and forecast of the industry for various regions.

Chapter 9 - Global Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029, by Drug Type

This part of the report on gonorrhea therapeutics market provides information about the key market particulars, breakdown and projection of the industry based on drug type.

Chapter 10 - Global Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029, by Therapy Type

This chapter of the report on gonorrhea therapeutics market offers information about the key market particulars, breakdown and projection of the market on the basis of therapy type.

Chapter 11 - Global Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029, by Route of Administration

This chapter of the report on gonorrhea therapeutics market offers information about the key market particulars, breakdown and projection of the market on the basis of route of administration.

Chapter 12 - Global Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029, by Distribution Channel

This section of the report on gonorrhea therapeutics market offers information about the key market particulars, breakdown and projection of the market on the basis of distribution channel.

Chapter 13 - North America Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029

This chapter of the report on gonorrhea therapeutics market offers incisive insights about North America gonorrhea therapeutics market, and also highlights the development trends that are impacting the growth of market in this region.

Chapter 14 - Latin America Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029

This chapter of the report on gonorrhea therapeutics market offers incisive insights about Latin America gonorrhea therapeutics market, and also highlights the development trends that are impacting the growth of market in this region.

Chapter 15 - Europe Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029

This chapter of the report on gonorrhea therapeutics market offers incisive insights about Europe gonorrhea therapeutics market, and also highlights the development trends that are impacting the growth of market in this region.

Chapter 16 - South Asia Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029

This chapter of the report on gonorrhea therapeutics market offers incisive insights about South Asia gonorrhea therapeutics market, and also highlights the development trends that are impacting the growth of market in this region.

Chapter 17 - East Asia Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029

This chapter of the report on gonorrhea therapeutics market offers incisive insights about East Asia gonorrhea therapeutics market, and also highlights the development trends that are impacting the growth of market in this region.

Chapter 18 – Oceania Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029

This chapter of the report on gonorrhea therapeutics market offers incisive insights about Oceania gonorrhea therapeutics market, and also highlights the development trends that are impacting the growth of market in this region.

Chapter 19 – Oceania Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029

This chapter of the report on gonorrhea therapeutics market offers incisive insights about Middle East and Africa gonorrhea therapeutics market, and also highlights the development trends that are impacting the growth of market in this region.

Chapter 20 - Competition Analysis

This vital section of the Fact.MR report provides detailed assessment of the gonorrhea therapeutics market’s structure, in addition to the profiles of the market players.

The report includes company profiles 

Teva Pharmaceutical Industries Ltd.,

  • Bayer AG,
  • Mylan N.V.
  • Merck & Co.
  • Allergan plc
  • Hoffmann-La Roche Ltd. 
  • Sanofi S.A.
  • Baxter International Inc
  • GlaxoSmithKline Plc.
  • Pfizer Inc.
  • Novartis AG.
1. Executive Summary
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
    2.3. Inclusions and Exclusions
3. Key Market Trends
4. Key Success Factors
5. Global Gonorrhea Therapeutics Market Demand (in Value US$ Mn) Analysis 2014-2018 and Forecast, 2019-2029
    5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018
    5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2029
        5.2.1. Y-o-Y Growth Trend Analysis
        5.2.2. Absolute $ Opportunity Analysis
6. Market Background
    6.1. Macro-Economic Factors
        6.1.1. Global GDP Growth Outlook
        6.1.2. Global Healthcare Industry Market Outlook
    6.2. Market Dynamics
        6.2.1. Drivers
        6.2.2. Restraints
        6.2.3. Opportunity Analysis
7. Global Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029, by Region
    7.1. Introduction
    7.2. Historical Market Size (US$ Mn) Analysis By Region, 2014 - 2018
    7.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2019-2029
        7.3.1. North America
        7.3.2. Latin America
        7.3.3. Europe
        7.3.4. Middle East and Africa (MEA)
        7.3.5. East Asia
        7.3.6. South Asia
        7.3.7. Oceania
    7.4. Market Attractiveness Analysis By Region
8. Global Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029, by Drug Type
    8.1. Introduction / Key Findings
    8.2. Historical Market Size (US$ Mn) Analysis By Drug Type, 2014 - 2018
    8.3. Current and Future Market Size (US$ Mn) and Forecast By Drug Type, 2019-2029
        8.3.1. Macrolide Antibiotics (Azithromycin)
        8.3.2. Third-Generation Cephalosporin
            8.3.2.1. Cefixime
            8.3.2.2. Cefotaxime
            8.3.2.3. Ceftizoxime 
            8.3.2.4. Ceftriaxone
            8.3.2.5. Cetriaxone
        8.3.3. Tetracycline Antibiotics (Doxycycline)
        8.3.4. Fluoroquinolones Antibiotics (Gemifloxacin)
        8.3.5. Aminoglycoside (Gentamicin)
        8.3.6. Aminocyclitol (Spectinomycin)
    8.4. Market Attractiveness Analysis By Drug Type
9. Global Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029, by Therapy Type
    9.1. Introduction / Key Findings
    9.2. Historical Market Size (US$ Mn) Analysis By Therapy Type, 2014 - 2018
    9.3. Current and Future Market Size (US$ Mn) and Forecast By Therapy Type 2019-2029
        9.3.1. Mono Therapy
        9.3.2. Dual Therapy
    9.4. Market Attractiveness Analysis By Therapy Type
10. Global Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029, by Route of Administration
    10.1. Introduction / Key Findings
    10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2014 - 2018
    10.3. Current and Future Market Size (US$ Mn) and Forecast By Route of Administration, 2019-2029
        10.3.1. Oral
        10.3.2. Intra Muscular
    10.4. Market Attractiveness Analysis By Route of Administration
11. Global Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029, by Distribution Channel
    11.1. Introduction / Key Findings
    11.2. Historical Market Size (US$ Mn) By Distribution Channel, 2014 - 2018
    11.3. Current and Future Market Size (US$ Mn) and Forecast By Distribution Channel, 2019-2029
        11.3.1. Institutional Sales
            11.3.1.1. Hospitals
            11.3.1.2. Speciality Clinics
        11.3.2. Retail Sales
            11.3.2.1. Hospital Pharmacy
            11.3.2.2. Retail Pharmacy
            11.3.2.3. Mail Order Pharmacy
    11.4. Market Attractiveness Analysis By Distribution Channel
12. North America Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2018-2029
    12.1. Introduction
    12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        12.3.1.  By Country
            12.3.1.1. U.S.
            12.3.1.2. Canada
        12.3.2. By Drug Type
        12.3.3. By Therapy Type
        12.3.4. By Route of Administration
        12.3.5. By Distribution Channel
    12.4. Market Attractiveness Analysis
        12.4.1. By Country
        12.4.2. By Drug Type
        12.4.3. By Therapy Type
        12.4.4. By Route of Administration
        12.4.5. By Distribution Channel
13. Latin America Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029
    13.1. Introduction
    13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        13.3.1.  By Country
            13.3.1.1. Brazil
            13.3.1.2. Mexico
            13.3.1.3. Rest of Latin America
        13.3.2. By Drug Type
        13.3.3. By Therapy Type
        13.3.4. By Route of Administration
        13.3.5. By Distribution Channel
    13.4. Market Attractiveness Analysis
        13.4.1. By Country
        13.4.2. By Drug Type
        13.4.3. By Therapy Type
        13.4.4. By Route of Administration
        13.4.5. By Distribution Channel
14. Europe Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029
    14.1. Introduction
    14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        14.3.1.  By Country
            14.3.1.1. Germany
            14.3.1.2. Italy
            14.3.1.3. France
            14.3.1.4. U.K.
            14.3.1.5. Spain
            14.3.1.6. BENELUX
            14.3.1.7. Russia
            14.3.1.8. Rest of Europe
        14.3.2. By Drug Type
        14.3.3. By Therapy Type
        14.3.4. By Route of Administration
        14.3.5. By Distribution Channel
    14.4. Market Attractiveness Analysis
        14.4.1. By Country
        14.4.2. By Drug Type
        14.4.3. By Route of Administration
        14.4.4. By Distribution Channel
15. South Asia Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029
    15.1. Introduction
    15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        15.3.1.  By Country
            15.3.1.1. India
            15.3.1.2. Thailand
            15.3.1.3. Indonesia
            15.3.1.4. Malaysia
            15.3.1.5. Rest of South Asia
        15.3.2. By Drug Type
        15.3.3. By Therapy Type
        15.3.4. By Route of Administration
        15.3.5. By Distribution Channel
    15.4. Market Attractiveness Analysis
        15.4.1. By Country
        15.4.2. By Drug Type
        15.4.3. By Therapy Type
        15.4.4. By Distribution Channel
16. East Asia Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029
    16.1. Introduction
    16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        16.3.1.  By Country
            16.3.1.1. China
            16.3.1.2. Japan
            16.3.1.3. South Korea
        16.3.2. By Drug Type
        16.3.3. By Therapy Type
        16.3.4. By Route of Administration
        16.3.5. By Distribution Channel
    16.4. Market Attractiveness Analysis
        16.4.1. By Country
        16.4.2. By Drug Type
        16.4.3. By Therapy Type
        16.4.4. By Route of Administration
        16.4.5. By Distribution Channel
17. Oceania Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029
    17.1. Introduction
    17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        17.3.1.  By Country
            17.3.1.1. Australia
            17.3.1.2. New Zealand
        17.3.2. By Drug Type
        17.3.3. By Therapy Type
        17.3.4. By Route of Administration
        17.3.5. By Distribution Channel
    17.4. Market Attractiveness Analysis
        17.4.1. By Country
        17.4.2. By Drug Type
        17.4.3. By Therapy Type
        17.4.4. By Route of Administration
        17.4.5. By Distribution Channel
18. Middle East and Africa Gonorrhea Therapeutics Market Analysis 2014-2018 and Forecast 2019-2029
    18.1. Introduction
    18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        18.3.1.  By Country
            18.3.1.1. GCC Countries
            18.3.1.2. Turkey
            18.3.1.3. Northern Africa
            18.3.1.4. South Africa
            18.3.1.5. Rest of Middle East and Africa
        18.3.2. By Drug Type
        18.3.3. By Therapy Type
        18.3.4. By Route of Administration
        18.3.5. By Distribution Channel
    18.4. Market Attractiveness Analysis
        18.4.1. By Country
        18.4.2. By Drug Type
        18.4.3. By Therapy Type
        18.4.4. By Route of Administration
        18.4.5. By Distribution Channel
19. Competition Analysis
    19.1. Market Analysis by Tier of Companies (Gonorrhea Therapeutics)
    19.2. Competition Dashboard
    19.3. Competition Deep Dive 
        19.3.1. Bayer AG
                19.3.1.1. Overview
                19.3.1.2. Key Financials
                19.3.1.3. Revenue Y-o-Y GROWTH
                19.3.1.4. Key Development
                19.3.1.5. Analyst Commentary
        19.3.2. GlaxoSmithKline Plc.
                19.3.2.1. Overview
                19.3.2.2. Key Financials
                19.3.2.3. Revenue Y-o-Y GROWTH
                19.3.2.4. Key Development
                19.3.2.5. Analyst Commentary
        19.3.3. Pfizer Inc.
               19.3.3.1. Overview
                19.3.3.2. Key Financials
                19.3.3.3. Revenue Y-o-Y GROWTH
                19.3.3.4. Key Development
                19.3.3.5. Analyst Commentary
        19.3.4. Allergan plc
                19.3.4.1. Overview
                19.3.4.2. Key Financials
                19.3.4.3. Revenue Y-o-Y GROWTH
                19.3.4.4. Key Development
                19.3.4.5. Analyst Commentary
        19.3.5. Novartis AG
               19.3.5.1. Overview
                19.3.5.2. Key Financials
                19.3.5.3. Revenue Y-o-Y GROWTH
                19.3.5.4. Key Development
                19.3.5.5. Analyst Commentary
        19.3.6. Sanofi S.A.
                19.3.6.1. Overview
                19.3.6.2. Key Financials
                19.3.6.3. Revenue Y-o-Y GROWTH
                19.3.6.4. Key Development
                19.3.6.5. Analyst Commentary
        19.3.7. Mylan N.V.
                19.3.7.1. Overview
                19.3.7.2. Key Financials
                19.3.7.3. Revenue Y-o-Y GROWTH
                19.3.7.4. Key Development
                19.3.7.5. Analyst Commentary
        19.3.8. Teva Pharmaceutical Industries Ltd.
                19.3.8.1. Overview
                19.3.8.2. Key Financials
                19.3.8.3. Revenue Y-o-Y GROWTH
                19.3.8.4. Key Development
                19.3.8.5. Analyst Commentary
        19.3.9. Baxter International Inc.
                19.3.9.1. Overview
                19.3.9.2. Key Financials
                19.3.9.3. Revenue Y-o-Y GROWTH
                19.3.9.4. Key Development
                19.3.9.5. Analyst Commentary
        19.3.10. Hoffmann-La Roche Ltd.
                19.3.10.1. Overview
                19.3.10.2. Key Financials
                19.3.10.3. Revenue Y-o-Y GROWTH
                19.3.10.4. Key Development
                19.3.10.5. Analyst Commentary
        19.3.11. Merck & Co.
                19.3.11.1. Overview
                19.3.11.2. Key Financials
                19.3.11.3. Revenue Y-o-Y GROWTH
                19.3.11.4. Key Development
                19.3.11.5. Analyst Commentary
20. Forecast Assumptions: Relevance and Impact
21. Assumptions and Acronyms Used
22. Research Methodology

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Gonorrhea Therapeutics Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2019 to 2029